Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: Missed opportunities for vaccination

Hepatology

Volumn 42, Issue 3, 2005, Pages 688-695

  Shim, Michael ^a   Khaykis, Inessa ^a   Park, James ^a   Bini, Edmund J ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEALTH PROMOTION; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION SENSITIVITY; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUPERINFECTION; VACCINATION;

AGED; DISEASE SUSCEPTIBILITY; ETHNIC GROUPS; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS C, CHRONIC; HOMELESS PERSONS; HOSPITALS, VETERANS; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; VIRAL HEPATITIS VACCINES;

EID: 24144464530     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20830     Document Type: Article

References (49)

1. Keeffe EB. Occupational risk for hepatitis A: a literature-based analysis. J Clin Gastroenterol 2004;38:440-448.
2. Centers for Disease Control and Prevention. Public health dispatch: multistate outbreak of hepatitis A among young adult concert attendees-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:844-845.
3. Cotter SM, Sansom S, Long T, Koch E, Kellerman S, Smith F, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis 2003;187:1235-1240.
4. Cooksley WG. What did we learn from the Shanghai hepatitis A epidemic? J Viral Hepat 2000;7(Suppl 1):1-3.
5. Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis 2004;38:705-715.
6. Centers for Disease Control and Prevention. Foodborne transmission of hepatitis A-Massachusetts, 2001. MMWR Morb Mortal Wkly Rep 2003;52:565-567.
7. Hutin YJ, Pool V, Cramer EH, Nainan OV, Weth J, Williams IT, et al. A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. N Engl J Med 1999;340:595-602.
8. Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 2003;21:2224-2233.
9. O'Donovan D, Cooke RP, Joce R, Eastbury A, Waite J, Stene-Johansen K. An outbreak of hepatitis A amongst injecting drug users. Epidemiol Infect 2001;127:469-473.
10. Koff RS. Hepatitis A. Lancet 1998;351:1643-l649.
11. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1-37.
12. Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, Weinberg M. The cost of hepatitis A infections in American adolescents and adults in 1997. HEPATOLOGY 2000;31:469-473.
13. Bianco E, Stroffolini T, Spada E, Szklo A, Marzolini F, Ragni P, et al. Case fatality rate of acute viral hepatitis in Italy: 1995-2000: an update. Dig Liver Dis 2003;35:404-408.
14. Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, et al. The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies. J Infect Dis 1998;178:1579-1584.
15. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-290.
16. Wang JY, Lee SD, Tsai YT, Lo KJ, Chiang BN. Fulminant hepatitis A in chronic HBV carrier. Dig Dis Sci 1986;31:109-111.
17. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989;110:838-839.
18. Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol 1995;90:201-205.
19. Pramoolsinsap C, Poovorawan Y, Hirsch P, Busagorn N, Attamasirikul K. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Patasitol 1999;93:745-751.
20. Lefilliatre P, Villeneuve JP. Fulminant hepatitis A in patients with chronic liver disease. Can J Public Health 2000;91:168-170.
21. Kyrlagkitsis I, Cramp ME, Smith H, Portmann B, O'Grady J. Acute hepatitis A virus infection: a review of prognostic factors from 25 years experience in a tertiary referral center. Hepatogastroenterology 2002;49: 524-528.
22. Almasio PL, Amoroso P. HAV infection in chronic liver disease: a rationale for vaccination. Vaccine 2003;21:2238-2241.
23. Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45:1-30.
24. World Health Organization. Public health control of hepatitis A: memorandum from a WHO meeting. Bull World Health Organ 1995;73:15-20.
25. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. HEPATOLOGY 2002;36(Suppl):S3-S20.
26. Department of Veterans Affairs. Hepatitis C Virus (HCV) Testing and Prevention Counseling Guidelines for VA Health Care Practitioners. Available at: http://www.va.gov/hepatitisc/pdf/ce203_testncounslguides. pdf. Accessed January 6, 2005.
27. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
28. American Liver Foundation. Position Statement on Hepatitis A and Vaccination. Available at http://www.liverfoundation.org/db/advocacy/l031. Accessed January 17, 2005.
29. American College of Gastroenterology. Chronic Liver Disease: A Primer for Vaccinations. Available at: http://www.acg.gi.org/physicianforum/publications/ index.html. Accessed December 15, 2004.
30. Cooksley WG. Consensus statement on the role of hepatitis A vaccination in patients with chronic liver disease. J Viral Hepat 2000;7(Suppl 1):29-30.
31. Crowcroft NS, Walsh B, Davison KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health 2001; 4:213-227.
32. Koff RS. Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. J Clin Gastroenterol 2001;33:20-26.
33. Reiss G, Keeffe EB. Review article: hepatitis vaccination in patients with chronic liver disease. Aliment Pharmacol Ther 2004;19:715-727.
34. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
35. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001;96:858-863.
36. Duncan M, Hirota WK, Tsuchida A. Prescreening versus empirical immunization for hepatitis A in patients with chronic liver disease: a prospective cost analysis. Am J Gastroenterol 2002;97:1792-1795.
37. Sjogren MH. Preventing acute liver disease in patients with chronic liver disease. HEPATOLOGY 1998;27:887-888.
38. Kiefer LA, Honish A, Predy G, Talbot JA. The seroprevalence of hepatitis A and B in people testing positive for hepatitis C. CMAJ 2000;162:207-208.
39. Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepatol 2005;12:101-105.
40. Arguedas MR, McGuire BM, Fallon MB. Implementation of vaccination in patients with cirrhosis. Dig Dis Sci 2002;47:384-387.
41. Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. HEPATOLOGY 1998;27:881-886.
42. Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. HEPATOLOGY 2001;34:28-31.
43. Jacobs RJ, Koff RS, Meyerhoff AS. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A. Am J Gastroenterol 2002; 97:427-434.
44. Arguedas MR, Heudebert GR, Fallon MB, Stinnett AA. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C viral infection in the United States. Am J Gastroenterol 2002;97:721-728.
45. Dumot JA, Barnes DS, Younossi Z, Gordon SM, Avery RK, Domen RE, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999;94:1601-1604.
46. Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001;72:272-276.
47. Lee SD, Chan CY, Yu MI, Wang YJ, Chang FY, Lo KJ, et al. Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997;52:215-218.
48. Nothdurft HD, Dietrich M, Zuckerman JN, Knobloch J, Kern P, Vollmar J, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002;20:1157-1162.
49. Joines RW, Blatter M, Abraham B, Xie F, De Clercq N, Baine Y, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrixand Engerix-B) in adults. Vaccine 2001;19:4710-4719.